11/19
08:20 am
neo
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment [Yahoo! Finance]
Medium
Report
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment [Yahoo! Finance]
11/19
08:15 am
neo
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
Medium
Report
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
11/14
08:22 am
neo
Felicia Williams Joins NeoGenomics Board of Directors [Yahoo! Finance]
Medium
Report
Felicia Williams Joins NeoGenomics Board of Directors [Yahoo! Finance]
11/14
08:10 am
neo
Felicia Williams Joins NeoGenomics Board of Directors
Medium
Report
Felicia Williams Joins NeoGenomics Board of Directors
11/8
07:00 am
neo
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Low
Report
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/6
08:07 am
neo
NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
Medium
Report
NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
11/6
06:42 am
neo
NeoGenomics Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]
Low
Report
NeoGenomics Third Quarter 2024 Earnings: EPS Beats Expectations [Yahoo! Finance]
11/6
02:22 am
neo
NeoGenomics Inc (NEO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
NeoGenomics Inc (NEO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... [Yahoo! Finance]
11/5
07:00 am
neo
NeoGenomics Reports Third Quarter 2024 Results
Medium
Report
NeoGenomics Reports Third Quarter 2024 Results
10/22
09:01 am
neo
NeoGenomics receives New York state approval for its solid tumor test [Seeking Alpha]
Low
Report
NeoGenomics receives New York state approval for its solid tumor test [Seeking Alpha]
10/22
08:14 am
neo
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test [Yahoo! Finance]
Low
Report
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test [Yahoo! Finance]
10/22
08:10 am
neo
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
Low
Report
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
10/15
07:30 am
neo
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
Low
Report
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
10/8
11:34 am
neo
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
Low
Report
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
10/8
08:14 am
neo
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia [Yahoo! Finance]
Low
Report
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia [Yahoo! Finance]
10/8
08:10 am
neo
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
Low
Report
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
9/25
01:47 pm
neo
Freenome Announces CEO Transition [Yahoo! Finance]
Low
Report
Freenome Announces CEO Transition [Yahoo! Finance]
9/25
08:09 am
neo
NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
Medium
Report
NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $19.00 price target on the stock.
9/24
08:09 am
neo
NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $18.00 price target on the stock.
Low
Report
NeoGenomics, Inc. (NASDAQ: NEO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $18.00 price target on the stock.
9/23
06:47 pm
neo
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
Low
Report
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
9/23
04:09 pm
neo
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase [Yahoo! Finance]
Neutral
Report
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase [Yahoo! Finance]
9/11
08:19 am
neo
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment [Yahoo! Finance]
Medium
Report
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment [Yahoo! Finance]
9/11
08:05 am
neo
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
Medium
Report
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
8/29
08:05 am
neo
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Low
Report
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference